Issue 83

Psilocybin Services Act

Oregon’s Psilocybin Services Act

In a milestone for psychedelic healthcare, Oregon has published the first regulations for its psilocybin framework – governing product, testing and training programmes.

The US state became the first to vote to legalise psilocybin, with several others expected to follow suit. Many will look to Oregon as a case study, and if the framework is successful, it could be replicated across the nation.

As a result, the legislation adopted in Oregon could have significant implications for the roll-out of psychedelic medicine in North America.

READ MORE

DRUG POSSESSION TO BE DECRIMINALISED IN B.C.

From January 2023, adults in British Columbia will be able to possess 2.5 grams of opioids, cocaine and MDMA.

Read More

IS PSYCHEDELIC MEDICINE THE UK'S BIG OPPORTUNITY?

Forbes outlines why the UK’s regulatory framework positions it to become a leader in psychedelic healthcare.

Read More

BUSINESS AND INVESTMENT

Novamind reports Q3 2022 financial results.

Wesana reports Q1 2022 financial results.

Silo Wellness to acquire Dyscovry Science.

Filament Health enters into supply agreement with Optimi Health.

Biomind’s Phase II study with 5-MeO-DMT analogue approved.

Psychedelic-assisted therapy retreats target corporate executives.

Cybin submits IND application for Phase I/IIa study.

Psychedelic medicines and the opioid epidemic.

Lennham Pharmaceuticals patents administration methods.

SCIENCE AND RESEARCH

atai introduces grant for psychedelic research at Massachusetts General Hospital.

Using ketamine to discover a new pathway in depression.

MAPS’ MDMA-assisted therapy training programme.

High expectations add to challenges in clinical trials.

The potential of psychedelic medicines to treat autism.

REGULATION AND LEGISLATION

Maryland bill to provide free psychedelic healthcare to veterans.

East Lansing, Michigan City Council rejects decriminalisation resolution.

Colorado initiates present competing visions for psychedelic healthcare.